Matinas BioPharma Files Routine 8-K

TL;DR

**Matinas BioPharma just dropped a routine 8-K, nothing major to see here.**

AI Summary

Matinas BioPharma Holdings, Inc. filed an 8-K on February 26, 2024, to disclose general information under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing indicates no specific material events, dollar amounts, or changes in operations, serving primarily as a routine update to the SEC.

Why It Matters

This filing is a standard regulatory update, indicating ongoing compliance but no immediate significant news for investors or the company's operational status.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure with no indication of adverse events or significant changes.

Key Players & Entities

• Matinas BioPharma Holdings, Inc. (company) — Registrant
• SEC (company) — Regulatory body
• February 26, 2024 (date) — Date of earliest event reported and filing date

FAQ

Filing Documents

• form8-k.htm (8-K) — 53KB
• ex99-1.htm (EX-99.1) — 28KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-24-007772.txt ( ) — 269KB
• mtnb-20240226.xsd (EX-101.SCH) — 3KB
• mtnb-20240226_lab.xml (EX-101.LAB) — 33KB
• mtnb-20240226_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On February 26, 2024, Matinas BioPharma Holdings, Inc. (the "Company") provided an update for its ongoing Compassionate/Expanded Use Access Program (the "Program") with MAT2203, the Company's proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B. A copy of the press release is furnished as Exhibit 99. 1 hereto and incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01. Other Events. On February 26, 2024, the Company announced that all patients who transitioned to its MAT2203 product candidate after developing renal toxicity following treatment with AmBisome (liposomal amphotericin B) saw a reversal of renal impairment with a return to baseline renal function with no subsequent renal issues. 19 patients to date have been enrolled in the Program at multiple healthcare institutions, including the University of Michigan, Johns Hopkins, Nationwide Children's Hospital, City of Hope, Vanderbilt University Medical Center, the National Institutes of Health, Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and the University of California, San Diego School of Medicine. The majority of enrolled patients are post-transplant or are undergoing treatment for underlying malignancies. The infections being treated with MAT2203 include a variety of micro-organisms (including Aspergillus , Mucorales species , Candidiasis , Fusarium and suspected Coccidioides ) occurring at multiple sites of infection, including brain, bladder/colon, bone, lung, sinus, and skin. Most patients were receiving AmBisome prior to enrollment but developed treatment-limiting nephrotoxicity and most also required treatment for either azole-resistant organisms or had clinically failed azole therapy and had no other treatment options. Of the 19 patients enrolled in the Program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2203. 12 of the 15 patients had either complete clinical resolution or objective improvement in clinical markers of infection (including radiologic and mycologic). Of the 5 patients who completed their full individually specified course of treatment (ranging from 2 weeks to 1 year, depending on the infection) - all have had complete clinical resolution with no relapses or recurrence of their infection. 5 additional patients have shown objective improvement in clin

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated February 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -3-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: February 26, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -4-

View Full Filing

View this 8-K filing on SEC EDGAR